Table 2. PANSS Scores (Total, Positive, and Negative) for Phases 1 and 2.
| SPCD Phase | Total Score, Mean (SD) | Positive Subscale Score, Mean (SD) | Negative Subscale Score, Mean (SD) | |||
|---|---|---|---|---|---|---|
| SNP | Placebo | SNP | Placebo | SNP | Placebo | |
| Phase 1 (n = 52) | ||||||
| Baseline | 83.6 (10.0) | 79.8 (8.9) | 24.9 (3.5) | 22.5 (3.2) | 20.9 (5.5) | 20.9 (4.8) |
| End | 77.6 (12.2) | 76.7 (11.0) | 23.1 (4.6) | 21.3 (3.6) | 19.1 (4.7) | 19.8 (5.1) |
| Change | −6.0 (11.3) | −2.5 (7.1) | −1.8 (1.9) | −0.8 (2.8) | −1.9 (4.2) | −1.0 (2.8) |
| Phase 2 (n = 32) | ||||||
| Baseline | 74.0 (12.0) | 78.8 (10.1) | 20.7 (3.6) | 21.8 (3.6) | 18.5 (5.8) | 20.8 (4.4) |
| End | 71.8 (10.6) | 74.7 (9.0) | 21.3 (4.6) | 22.4 (3.5) | 18.1 (6.2) | 19.8 (4.7) |
| Change | −1.8 (8.2) | −4.2 (6.4) | 0.5 (3.8) | 0.6 (2.2) | −0.2 (0.9) | −0.9 (3.0) |
Abbreviations: PANSS, Positive and Negative Syndrome scale; SNP, sodium nitroprusside; SPCD, sequential parallel comparison design.